Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin
NCT03899402Phase 3Active, not recruiting
- Sponsor
- University at Buffalo
- Start
- May 2019
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin, semaglutide in type 1 diabetes mellitus (T1D), sponsored by University at Buffalo. Started May 2019; status: active, not recruiting.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03899402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899402.